HOME >> BIOLOGY >> NEWS
Stowers Institute's Workman Lab demonstrates mechanism for decoding histone modification marks

Jerry Workman, Ph.D., Investigator, and Bing Li, Ph.D., Senior Research Associate in the Workman Lab, have published evidence demonstrating that a combinatorial action of multiple protein domains is required to read a histone modification.

Published in today's issue of Science, their paper, "Combined action of PHD and Chromo domains directs the Rpd3S complex to deacetylate transcribed chromatin," used a novel approach that allowed the team to measure the protein complex binding to modified chromatin.

"When cells transcribe genes, that part of the chromosome is opened and susceptible to inappropriate use. Cells demarcate transcribed regions of chromosomes with a landmark the lysine 36 methylation of histone H3," explains Dr. Li. "We found that combination of two critical protein domains within a histone deacetylase complex is essential for its recruitment to this modified chromatin in transcribed regions. This specific recognition re-closes the chromosome and ensures genome integrity during active transcription and maintains accurate transcription initiation."

Within chromatin-related complexes, compact structural parts of a protein, called "domains," are able to recognize specific histone modifications. However, until now it was unclear how such domains could target the correct protein complex to a specific site in the chromosome. In this case it takes the combined action of two protein domains to target the complexes to transcribe chromatin to re-close its structure.

The findings bear significantly on the understanding of Huntington's disease, which is marked by genetically programmed degeneration of neurons in certain areas of the brain.

"The histone modification we focused on in this study, K36 methylation, is catalyzed by the human protein HYPB that interacts with the Huntington's disease protein known as huntingtin," said Dr. Workman. "Our findings may one day assist in the design of therapeutic or preve
'"/>

Contact: Marie Jennings
mfj@stowers-institute.org
816-926-4015
Stowers Institute for Medical Research
18-May-2007


Page: 1 2

Related biology news :

1. Stowers Institute scientist named Searle Scholar
2. Stowers scientists clarify role of tumor suppressor gene
3. Stowers scientists demonstrate mechanism of vertebral formation
4. Fourth Stowers researcher awarded Basil OConnor Award
5. Stowers researcher answers fundamental question of cell death
6. Stowers researcher publishes DNA double-strand break repair discovery in Science
7. Stowers Institute scientist named American Cancer Society research professor
8. New study demonstrates important role of glia in circadian timing
9. BEMA Fentanyl demonstrates substantial transmucosal delivery
10. Xie Lab demonstrates the role of microRNA pathway
11. Rong Li Lab demonstrates the process of mammalian egg maturation

Post Your Comments:
(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: